<DOC>
	<DOCNO>NCT01511965</DOCNO>
	<brief_summary>Vitiligo depigmenting skin disease common . Vitiligo cause disappearance melanocyte epidermis . Vitiligo cause disfigurement , psychological social , sound lot quality life . Currently standard treatment vitiligo ultraviolet ray ( UV ) , allow 50 % repigmentation lesion half patient . The application autologous epidermal cell liquid phase promise new therapeutic approach vitiligo . The main goal study compare prospectively repigmentation vitiligo lesion induce application autologous epidermal cell liquid phase associate light therapy light therapy alone . Study 's secondary goal : compare application epidermal cell phototherapy alone phototherapy , respect : - Obtain repigmentation &gt; 70 % ( threshold consider aesthetically relevant ) - The occurrence adverse event - Patient satisfaction regard efficacy safety treatment</brief_summary>
	<brief_title>Study Applications Autologous Epidermal Cells Liquid Phase Treatment Vitiligo</brief_title>
	<detailed_description>MAIN CRITERIA - Rates repigmentation vitiligo lesion 12 month - The lesion layer define investigator Month 0 , Month 3 , Month 6 Month 12 analyze image analysis system manage computer . - Digital photo take order illustrate quantitative result . SECONDARY CRITERIA - Repigmentation &gt; 70 % vitiligo lesion 12 month - Rates repigmentation vitiligo lesion 12 month - Side effect : frequency , severity time occurrence report treatment . Side effect classify grade accord World Health Organization ( WHO ) criterion . - Patient satisfaction effectiveness tolerance study use visual analogue scale grade 0 10 .</detailed_description>
	<mesh_term>Vitiligo</mesh_term>
	<criteria>Elderly patient least 18 year Subjects stable vitiligo ( new injury lack expansion exist lesion last 12 month ) , least two vitiligo lesion least 10 cm2 locate anatomical location , require treatment UVB phototherapy . Topic vitiligo Subjects agree blood research Human immunodeficiency virus ( HIV ) , Human Tlymphotropic virus 1 ( HTLV1 ) , hepatitis B , hepatitis C , human Chorionic Gonadotropinfor ( hCG ) woman . For woman childbearing age , use effective contraception ( birth control pill Intrauterine Device ( IUD ) ) duration study Topics able participate respect . Topics affiliate social security . Topics sign write informed consent start study . Pregnant nursing woman . Subjects history keloid scarring . Subjects history melanoma . Subjects photodermatitis . Topics take photosensitize treatment . Subjects receive treatment vitiligo 4 week enrollment . Subjects HIV testing , hepatitis B hepatitis C positive . Major Topics protect law</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>